PharmaTher Holdings Ltd. SEDAR Filings

News 2026-05-27

Open PDF

PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines

News release - English.pdf

News 2026-05-13

Open PDF

PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

News release - English.pdf

Results 2026-04-29

Open PDF

Interim MD&A - English.pdf

Results 2026-04-29

Open PDF

Interim financial statements/report – English.pdf

News 2026-04-21

Open PDF

PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness

News release - English.pdf

News 2026-04-20

Open PDF

PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides

News release - English.pdf

News 2026-04-16

Open PDF

PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery

News release - English.pdf

News 2026-04-13

Open PDF

PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology

News release - English.pdf

News 2026-03-26

Open PDF

PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches

News release - English.pdf

News 2026-03-03

Open PDF

PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market

News release - English.pdf

News 2026-02-02

Open PDF

PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success

News release - English.pdf

Results 2026-01-30 Financials

Open PDF

Interim MD&A - English.pdf

Results 2026-01-30 Financials

Open PDF

Interim financial statements/report – English.pdf

News 2026-01-14

Open PDF

PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs

News release - English.pdf

News 2026-01-02

Open PDF

PharmaTher CEO Publishes Letter to Shareholders

News release - English.pdf

Transactions 2025-12-02 M&A

Open PDF

PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise

News release - English.pdf

Transactions 2025-11-17 M&A

Open PDF

PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program

News release - English.pdf

Results 2025-10-30 Financials

Open PDF

Interim financial statements/report – English.pdf

Results 2025-10-30 Financials

Open PDF

Interim MD&A - English.pdf

News 2025-10-17

Open PDF

News release - English.pdf

News 2025-10-16

Open PDF